Genomic Risk Classifiers in Prostate Cancer: Precise Tools Awaiting Clinical Standardization
GRCs for prostate cancer show promise but lack standardization, with usage patterns varying by income and geography in clinical practice.
Prostate Cancer
Latest Post
Decipher Test Identifies Prostate Cancer Patients Who Benefit Most from Chemotherapy
Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy, sparing others from unnecessary...
FDA Expands Pluvicto Indication as PARP Inhibitors Advance Biomarker-Driven Prostate Cancer Strategies
FDA expands Pluvicto for earlier use while PARP inhibitors show benefit in BRCA1/2+ patients, advancing...
FDA Grants De Novo Authorization to ArteraAI Prostate: First AI Tool for Prostate Cancer Prognosis
FDA grants de novo authorization to ArteraAI Prostate, first AI tool to prognosticate long-term outcomes...
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
FDA approves darolutamide (Nubeqa) for mCSPC: 46% reduction in disease progression risk vs placebo in...
